Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients
| Autor: | Michael Rudoy, Axel Scherer, Hans-Bernd Prisack, Peter Arne Gerber, Wilfried Budach, Gerald Steinbach, V Shukla, Matthias Peiper, N.P. Hoff, Andreas Erhardt, Kai Kammers, G Matuschek, Hans Bojar, Wolfram T. Knoefel, B Flehmig, Matthias Schauer, Andreas Schwarz, Bettina Alexandra Buhren, Edwin Bölke |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment lcsh:Medicine Sensitivity and Specificity Insulin-like growth factor-binding protein Cohort Studies Insulin-like growth factor Young Adult Insulin-Like Growth Factor II Internal medicine Neoplasms medicine Biomarkers Tumor Humans Prospective Studies Young adult Insulin-Like Growth Factor I Prospective cohort study Tumor marker Aged Aged 80 and over biology insulin like growth factor binding protein Growth factor Research lcsh:R Case-control study Cancer prognostic factors General Medicine Middle Aged medicine.disease Prognosis Insulin-Like Growth Factor Binding Protein 2 Endocrinology Insulin-Like Growth Factor Binding Protein 3 Case-Control Studies tumor marker biology.protein Female Follow-Up Studies |
| Zdroj: | European Journal of Medical Research European Journal of Medical Research, Vol 16, Iss 10, p 451 (2011) |
| ISSN: | 0949-2321 |
| Popis: | Objective Insulin-like growth factor (IGF)-1, -2 and Insulin like growth factor binding proteins (IGFBP) are involved in the proliferation and differentiation of cells. It has never been evaluated, if the IGF-system can serve as a tumor marker in neoplasms. Methods In our prospective study 163 patients with colorectal cancer (22), prostate cancer (21), head and neck tumors (17), lymphomas (20), lung cancer (34) and other entities (49) were analysed for their IGF and IGFBP serum levels at the beginning and the end of radiotherapy and compared to 13 healthy people. Subgroups of patients with local tumor disease versus metastatic disease, primary and recurrent therapy and curative versus palliative therapy were compared. Results The serum levels of IGF-2 were significantly elevated in patients with prostate and colorectal cancer. However, sensitivity and specificity were only 70%. IGFBP-2 serum levels were elevated in patients with head and neck tumors. Again sensitivity and specificity were only 73%. A difference between local disease and metastatic disease could not be found. A difference between IGF serum levels before and after radiotherapy could not be detected. Conclusion The IGF-system cannot serve as a new tumor marker. The detected differences are very small, sensitivity and specificity are too low. IGF measurement is not useful for the evaluation of the success of radiotherapy in malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink